S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Biogen (BIIB) Stock Price, News & Analysis

$192.16
-2.99 (-1.53%)
(As of 04/17/2024 ET)
Today's Range
$192.01
$195.55
50-Day Range
$195.15
$244.74
52-Week Range
$192.01
$319.76
Volume
1.32 million shs
Average Volume
1.15 million shs
Market Capitalization
$27.93 billion
P/E Ratio
24.08
Dividend Yield
N/A
Price Target
$298.96

Biogen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
54.9% Upside
$297.73 Price Target
Short Interest
Healthy
2.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.65
Upright™ Environmental Score
News Sentiment
-0.03mentions of Biogen in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$202,030 Sold Last Quarter
Proj. Earnings Growth
13.95%
From $15.48 to $17.64 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.87 out of 5 stars

Medical Sector

23rd out of 914 stocks

Biological Products, Except Diagnostic Industry

4th out of 139 stocks

BIIB stock logo

About Biogen Stock (NASDAQ:BIIB)

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Stock Price History

BIIB Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Biogen (BIIB) to Release Quarterly Earnings on Wednesday
Biogen Inc. (NASDAQ:BIIB) Sees Large Increase in Short Interest
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Biogen Is Suffering From Doubts About the Future
Biogen (NASDAQ:BIIB) Sets New 12-Month Low at $201.82
Reviewing Biogen (NASDAQ:BIIB) and BioAtla (NASDAQ:BCAB)
Biogen: Doubts About The Future
Looking Into Biogen's Recent Short Interest
BIIB May 2024 210.000 call
BIIB May 2024 230.000 call
Forecasting The Future: 18 Analyst Projections For Biogen
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
4/17/2024
Next Earnings (Confirmed)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
7,570
Year Founded
1978

Price Target and Rating

Average Stock Price Target
$297.73
High Stock Price Target
$373.00
Low Stock Price Target
$213.00
Potential Upside/Downside
+55.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
27 Analysts

Profitability

Net Income
$1.16 billion
Pretax Margin
13.19%

Debt

Sales & Book Value

Annual Sales
$9.84 billion
Cash Flow
$17.99 per share
Book Value
$102.14 per share

Miscellaneous

Free Float
144,489,000
Market Cap
$27.93 billion
Optionable
Optionable
Beta
-0.02

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Christopher A. Viehbacher (Age 63)
    President, CEO & Director
    Comp: $487.94k
  • Mr. Michael R. McDonnell CPA (Age 60)
    Executive VP & CFO
    Comp: $2.12M
  • Ms. Nicole Murphy
    Head of Pharmaceutical Operations & Technology
  • Ms. Susan H. Alexander Esq.Ms. Susan H. Alexander Esq. (Age 67)
    Executive VP & Chief Legal Officer
    Comp: $2.2M
  • Dr. Ginger Gregory (Age 56)
    Executive VP & Chief Human Resources Officer
    Comp: $1.59M
  • Ms. Robin C. Kramer (Age 58)
    Senior VP & Chief Accounting Officer
  • Mr. Charles E. Triano
    Senior VP & Head of Investor Relations
  • Ms. Natacha Gassenbach
    Chief Communication Officer & Head of Corporate Affairs
  • Mr. Adam Keeney Ph.D.
    Executive VP & Head of Corporate Development
  • Ms. Alisha A. Alaimo
    President & Head of North America

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Biogen Inc.:

  • Biogen Inc. offers a diverse portfolio of therapies for treating neurological and neurodegenerative diseases, including cutting-edge treatments like ADUHELM for Alzheimer's disease.
  • The company has a strong pipeline of products under development for various conditions, indicating potential future growth and revenue streams.
  • Biogen's collaboration and license agreements with reputable companies demonstrate strategic partnerships that could lead to innovative breakthroughs in the biotechnology sector.
  • Recent positive developments, such as successful clinical trials or regulatory approvals, can boost investor confidence and drive stock price appreciation.
  • Biogen's focus on developing biosimilars can provide cost-effective alternatives to existing biologic drugs, potentially increasing market share and profitability.

Cons

Investors should be bearish about investing in Biogen Inc. for these reasons:

  • Market competition in the biotechnology industry is intense, leading to potential challenges in maintaining market share and pricing power.
  • Regulatory uncertainties, such as changes in healthcare policies or drug approval processes, can impact Biogen's operations and financial performance.
  • Dependency on a few key products for a significant portion of revenue can pose risks if any of these products face setbacks or patent expirations.
  • Volatility in the stock price of biotech companies like Biogen due to factors like clinical trial results, regulatory decisions, or market sentiment can lead to investment risks.
  • Macroeconomic factors, such as global economic conditions or healthcare spending trends, can influence the demand for Biogen's products and affect its financial results.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

BIIB Stock Analysis - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 9 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price target for 2024?

27 Wall Street research analysts have issued 12 month target prices for Biogen's shares. Their BIIB share price targets range from $213.00 to $373.00. On average, they anticipate the company's stock price to reach $297.73 in the next twelve months. This suggests a possible upside of 54.9% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2024?

Biogen's stock was trading at $258.77 at the beginning of 2024. Since then, BIIB shares have decreased by 25.7% and is now trading at $192.16.
View the best growth stocks for 2024 here
.

Are investors shorting Biogen?

Biogen saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,550,000 shares, an increase of 33.5% from the March 15th total of 2,660,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the days-to-cover ratio is presently 3.0 days. Approximately 2.5% of the shares of the stock are sold short.
View Biogen's Short Interest
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our BIIB earnings forecast
.

How can I listen to Biogen's earnings call?

Biogen will be holding an earnings conference call on Wednesday, April 24th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its earnings results on Tuesday, February, 13th. The biotechnology company reported $2.95 EPS for the quarter, missing the consensus estimate of $3.18 by $0.23. The biotechnology company earned $2.39 billion during the quarter, compared to analysts' expectations of $2.47 billion. Biogen had a trailing twelve-month return on equity of 14.91% and a net margin of 11.81%. During the same quarter last year, the company earned $4.05 earnings per share.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share guidance of 15.000-16.000 for the period, compared to the consensus estimate of 15.650. The company issued revenue guidance of -.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Saratoga Research & Investment Management (0.11%), Grimes & Company Inc. (0.03%), Gateway Investment Advisers LLC (0.03%), Cardinal Capital Management (0.02%), Czech National Bank (0.02%) and Gulf International Bank UK Ltd (0.01%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Eric K Rowinsky, Ginger Gregory, Priya Singhal and Susan H Alexander.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
This page (NASDAQ:BIIB) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners